Business
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of
About this update from Madrigal Pharmaceuticals, Inc.
[{"type":"text","content":"Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company’s leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver. The company will present more details at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m. PST. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations site, Events and Presentations page. “Madrigal is committed to building the industry-leading pipeline that will shape the future of MASH care and improve patient outcomes,” said Bill Sibold, Chief Executive Officer of Madrigal. “As the next wave of innovation moves toward combination therapies, Rezdiffra’s strong profile as a liver-directed, well-tolerated, once-daily oral therapy positions it as the ideal foundation. Our global license agreement for ervogastat aligns with our long-term leadership ambition, and we believe Madrigal is uniquely positioned to advance this promising Phase 2 asset and unlock its full clinical and commercial value through a development program focused on combination therapy with Rezdiffra.” “There is a compelling scientific rationale for studying ervogastat in combination with Rezdiffra,” said Professor Quentin Anstee, Ruth & Lionel Jacobson Chair of Personalised Medicine, Faculty of Medical Sciences, Newcastle University, and lead investigator on a prior Phase 2 ervogastat study. “A majority of patients in the Phase 2 study of ervogastat achieved...